Subscribe
Sign in
Subscribe
Sign in
GlobalData
GlobalData

Pharma

Diagnosed prevalent cases of obesity and overweight to reach 292 million in 2031 across 7MM, forecasts GlobalData

The diagnosed prevalent cases of obesity and overweight combined in the seven major markets (7MM*) are projected to increase at an annual growth rate (AGR) of 0.54% from 276.9 million in 2021 to nearly 292.0 million in 2031, forecasts GlobalData, a leading data and analytics company. GlobalData’s latest report, “Obesity and Obesity: Epidemiology Forecast to […]
Read more

Chinese regulators focus on homegrown COVID-19 therapies to tackle new variants, says GlobalData

The National Medical Products Administration (NMPA) of China has conditionally approved two homegrown oral drugs Simcere Pharmaceutical’s Xiannuoxin and Shanghai Junshi Biosciences‘ Mindevir for the treatment of mild to moderate COVID-19. Drug regulators in China are focusing on approving homegrown antiviral therapies with the ability to tackle new COVID-19 variants, says GlobalData, a leading data […]
Read more

Moderna’s non-vaccine mRNA therapeutic set to generate $278 million in 2028 if approved, estimates GlobalData

Moderna recently confirmed that its Phase I/II study examining candidate mRNA-3927 is progressing. It also shared that data showed a decrease in the number of metabolic decompensation events (MDEs) in trials of mRNA-3927, and regulators seemed to be supportive of MDE as a primary endpoint for the study. Additionally, Moderna stated that all eligible participants […]
Read more

Trodelvy set to become Gilead’s blockbuster with expanded approval, predicts GlobalData

The FDA recently granted expanded approval for Gilead Sciences’ Trodelvy (sacituzumab govitecan-hziy) for patients with HR-positive/HER2-negative metastatic breast cancer who have received hormonal therapy and at least two additional therapies in the metastatic setting. Trodelvy gained approval by outperforming traditional chemotherapies in this patient group. The drug is expected to become a standard of care […]
Read more

Clinical hold on 4D Molecular’s Fabry program to rise chances for Sangamo to lead FD gene therapy market, says GlobalData

4D Molecular Therapeutics (4DMT), the California-based biotechnology company focused on developing gene therapies for rare and cardiovascular, pulmonary, and ophthalmic diseases, has recently been issued a clinical hold by the FDA for its Fabry Disease (FD) gene therapy program (4D-310).  4DMT and Sangam Therapeutics are the leading developers in the Fabry disease space, and with […]
Read more

Asundexian phase III trial critical for Bayer to become market leader in anticoagulation to prevent stroke in AF patients, says GlobalData

Following the enrollment of the first patient in Bayer’s Phase III OCEANIC-AF clinical trial of asundexian, a potential anticoagulant for stroke prevention in atrial fibrillation (AF) patients; Amy Murray, Healthcare Analyst at GlobalData, a leading data and analytics company, offers her view: “Despite advances in anticoagulation therapy over the last decade, the increased risk and […]
Read more

Potential association between ROBO2 and anthracycline-related cardiomyopathy in childhood cancer survivors holds important implications, says GlobalData

A genome-wide association study (GWAS) published in the Journal of Clinical Oncology has identified a potential association between a genetic variant, ROBO2, and anthracycline-related cardiomyopathy in childhood cancer survivors. The study has important implications as anthracyclines are a widely used chemotherapy drug class to treat various forms of cancer, with 50-60% of children with cancer […]
Read more

Olezarsen Fast Track FDA approval strengthens Ionis Pharmaceuticals outlook in dyslipidemia space, says GlobalData

Ionis Pharmaceuticals has recently received the US FDA Fast Track designation for its investigational therapy, olezarsen, in patients with familial chylomicronemia syndrome (FCS). Olezarsen is also being investigated in a Phase III clinical trial for severe hypertriglyceridemia (sHTG) in the US and several EU countries, including France, Germany, Italy, and the UK. If approved, olezarsen […]
Read more

Approved CD19 CAR-T agents to treat over 13,000 cancer patients annually by 2031, driving sales of Breyanzi and Yescarta, says GlobalData

The number of blood cancer patients receiving CD19-directed chimeric antigen receptor T-cell (CD19 CAR-T) therapies is set to boom over the next decade from approximately 3,700 patients in 2021 to nearly 13,500 patients in 2031. As such, Bristol-Myers Squibb’s Breyanzi and Gilead’s Yescarta are set to enjoy a lucrative period of high annual sales over […]
Read more

H2 2022 sees 10 billion drop in total forecast sales of COVID-19 vaccines between 2021 and 2028, says GlobalData

Despite the continued success of prophylactic vaccines such as Pfizer/BioNTech’s messenger RNA (mRNA) vaccine Comirnaty and spikes in COVID-19 case numbers over the winter, prophylactic COVID-19 vaccine sales forecasts have seen an average decline between H1 2022 and H2 2022 of 7% in their predicted total forecast sales between 2022 and 2028, says GlobalData, a […]
Read more

GlobalData slashes Moderna COVID-19 vaccine Spikevax sales forecast amid strong competition

It was an exceptional year for Moderna’s vaccine Spikevax, with forecast sales of $19.5 billion in 2022. However, increasing competition from Pfizer’s Comirnaty, Novavax’s Nuvaxovid, and COVID-19 therapeutics has forced GlobalData to slash Spikevax’s average annual sales forecast by 23% between H1 and H2 2022 in its Coronavirus Disease 2019 (COVID-19) Sector Forecast reports. Kevin […]
Read more

Uptake of long-awaited Humira biosimilar in US to be dictated by price, says GlobalData

Following the launch of Amgen’s Amjevita (adalimumab-atto), the first biosimilar to AbbVie’s cash-cow immunology biologic therapy, Humira (adalimumab), in the US on 31 January; Vinie Varkey, Managing Analyst, Immunology at GlobalData, a leading data and analytics company, offers her view: “For AbbVie, while the threat of adalimumab biosimilars to its blockbuster therapy are finally tangible […]
Read more

With expanded approval for Brukinsa, BeiGene poised to lead chronic lymphocytic leukemia market, says GlobalData

The FDA has recently granted expanded approval for BeiGene’s oral Bruton tyrosine kinase inhibitor (BTKi) Brukinsa (zanubrutinib) for patients with chronic lymphocytic leukemia (CLL) or small Lymphocytic Leukemia (SLL). Brukinsa has gained approval after outperforming Abbvie’s Imbruvica, which has been the standard of care in CLL for almost a decade. Brukinsa should largely replace Imbruvica […]
Read more
1 … 39 40 41 42 43 … 110